Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Publication date: Apr 11, 2019

This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Participants in MOMs will be offered the opportunity to enroll in this sub-study, which is designed to evaluate conceptual models of the mechanisms by which extended-release buprenorphine (BUP-XR), may improve mother-infant outcomes, compared to sublingual buprenorphine (BUP-SL). The additional data collected in this sub-study will be combined with data from the main MOMs trial. It is hypothesized that: (1) the buprenorphine blood levels will vary, depending on which formulation of buprenorphine was received, (2) the variation in buprenorphine blood levels will be associated with fetal behavior (including fetal heart rate variability) (3) the variation in buprenorphine blood levels will be associated with differences in mother outcomes (including medication adherence and illicit opioid use) (4) the variation in buprenorphine blood levels and in fetal behavior will be associated with infant outcomes (including neonatal opioid withdrawal syndrome and infant development).

Concepts Keywords
Blood Opioids
Buprenorphine Morphinans
Cincinnati RTT
CMA Drug rehabilitation
CTN Ethers
Extended Release Phenols
Fetal Buprenorphine
Heart Rate Variability MOMS Trial
Neonatal
NIDA
Opioid
PhD
Protocol
SL
Sublingual

Semantics

Type Source Name
pathway BSID Release
drug DRUGBANK Buprenorphine
gene UNIPROT COMMD3
disease MESH fetal heart rate
disease MESH medication adherence
disease MESH syndrome
disease DOID syndrome
disease MESH development
gene UNIPROT NR4A2
gene UNIPROT ALG3
gene UNIPROT PDC

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *